Daniel J. Brennan - Feb 11, 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP and CFO
Signature
/s/ Susan Thompson, Attorney-in-Fact
Stock symbol
BSX
Transactions as of
Feb 11, 2025
Transactions value $
-$3,078,622
Form type
4
Date filed
2/13/2025, 04:31 PM
Previous filing
Jan 6, 2025
Next filing
Feb 14, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Award $0 +33.9K +15.16% $0.00 258K Feb 11, 2025 Direct F1
transaction BSX Common Stock Tax liability -$1.74M -16.4K -6.37% $105.98 241K Feb 11, 2025 Direct
transaction BSX Common Stock Options Exercise $246K +15.1K +6.25% $16.31 257K Feb 12, 2025 Direct F2
transaction BSX Common Stock Sale -$1.59M -15.1K -5.88% $105.07 241K Feb 12, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -15.1K -100% $0.00 0 Feb 12, 2025 Common Stock 15.1K $16.31 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F2 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024.
F3 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.778 to $105.28, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.